**List of Figures and Tables**

Fig 2.1 Models for Valuing a Company’s Projected Revenues

Fig 4.1 Cybersecurity

Fig 12.1 Drug Development Costs and Duration

Fig 12.2 The Different FDA NDA Application Tracks

Fig 13.1 Global Biologics and Biosimilar Markets by Sales, 2017

Fig 14.1 Applying the Network and Information Security Directive

Fig 16.1 Competitor Sales

Fig 16.2 Worldwide Sales for the Top 10 Condition II Drugs [this includes both a figure and a table – are they both necessary, or should they be separated?]

Fig 16.3 Clinical Development Success Rates (SR)

Fig 17.1 Adalimumab Biosimilars Competition, Sales Data and Forecast through 2024

Fig 18.1 Company C’s Position in Sector Ecosystem

Fig 18.2 Company C’s Position in User Network

Fig 18.3 Consumers of Company C Solutions

Fig 18.4 Company C’s Position un User Network

Fig 18.5 DPI Advantages

Fig 18.6 DPI Regional Trends

Fig 19.1 Ireland Wind Capacity Projections

Fig 19.2 Serbia Electricity Consumption

Fig 19.3 Company D’s Hungary Projections

Fig 19.4 Company D Project Breakdown

Table 4.1 Comparative Market Sector Analysis of Competing Applications

Table 5.1 New Stem Cell Technologies

Table 5.2 Valuation Parameters

Table 5.3 [Blue table/box following Table 5.2]

Table 5.4 ROV Valuation

Table 5.5 Pre-patent Expiration Scenarios

Table 5.6 NPV Valuation

Table 5.7 Comprehensive Evaluation

Table 8.1 Recognized Psychology and Behavioral Biases that Can Affect Financial Decisions and Valuations

Table 11.1 Success Rates of Solar and Wind Energy Projects

Table 11.2 [No title – Valuation of Technology?]

Table 12.1 Ride-sharing Sales

Table 14.1 [No title – Network Security Market]

Table 14.2 Four Major Drivers Affecting the Adoption of Network Security Measures

Table 14.3 Major Constraints Affecting the Adoption of Network Security

Table 16.1 Company A’s R&D and Clinical Testing Status

Table 16.2 Potential Direct Competitors for Company A’s Products

Table 16.3 Company A’s Clinical Applications

Table 16.4 Main Valuation Parameters for Conditions I and II

Table 16.5 Company A Pipeline Analysis

Table 16.6 Primary Valuation Parameters of Company A’s Technological Platform

Table 16.7 Company A Pipeline Analysis

Table 16.8 Company A Sensitivity Analysis

Table 16.9 Company A Forecasts

Table 16.10 Company A CAPM Model

Table 17.1 Key Competitors of Company B: A Comparative Analysis

Table 17.2 Primary Valuation Parameters of Company B’s Technological Platform

Table 17.3 Company B Valuation Elements

Table 17.4 Company B Sensitivity Analysis

Table 17.5 Company B’s CAPM Model

Table 17.6 Company B’s Competitors’ Capital Rounds and Recent M&As

Table 18.1 DPI Market Segmentation

Table 18.2 Major Drivers Impacting Adoption of DPI

Table 18.3 Major Constraints Impacting Adoption of DPI

Table 18.4 Company C Five-Year Forecast

Table 19.1 Hungary Renewable Electricity Capacity

Table 19.2 Company D’s Israeli and Irish Holdings

Table 19.3 Company D Project Breakdown

Table 19.4 Company D’s Project Variables

Table 19.5 Company D’s Pipeline Values

Table 19.6 Company D Equity Breakdown

Table 19.7 Company D Sensitivity Analysis